明德生物(002932.SZ)實控人之一陳莉莉解押500萬股及再質押590萬股
格隆匯8月16日丨明德生物(002932.SZ)公佈,公司近日接到控股股東、實際控制人之一陳莉莉的通知,獲悉其將所持有的部分公司股份在華泰證券進行解除質押及再質押,並在中國證券登記結算有限責任公司深圳分公司辦理了股權解除質押及質押登記手續。其中,解除質押500萬股,質押590萬股。
截至公告披露日,陳莉莉持有公司股份2024.3263萬股,佔公司總股本的30.4%。其所持有上市公司股份累計被質押的數量為590萬股,佔其所持有公司股份總數的29.15%,佔公司總股本的比例為8.86%
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.